Open Actively Recruiting

XVIVO Heart Perfusion System (XHPS) With Supplemented XVIVO Heart Solution (SXHS)

About

Brief Summary

The purpose of this study is to evaluate if Non-Ischemic Heart Preservation (NIHP) of extended criteria donor hearts using the XVIVO Heart Preservation System (XHPS) is a safe and effective way to preserve and transport hearts for transplantation.

Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase 2

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

Recipient Inclusion Criteria:

  • Age ≥18 years.
  • Signed informed consent form (ICF).
  • Listed for heart transplantation

Recipient Exclusion Criteria:

  • Previous solid organ or bone marrow transplantation.
  • Requires a multi-organ transplant.
  • Subject is enrolled and ongoing in another investigational pharmaceutical or medical device clinical trial (Exception: observational studies are permitted).
  • Subject is on mechanical circulatory support pre-transplant other than durable LVAD, Impella or intra-aortic balloon pump.
  • History of complex congenital heart disease ie: single ventricle physiology (Per Investigators discretion).
  • Subject on renal replacement therapy/dialysis.
  • Ventilator dependence (subject is intubated at time of transplant/unable to provide consent or re-affirmation of consent).
  • Sensitized subject is undergoing desensitization treatment.

Donor Inclusion Criteria:

  • Estimated Cross Clamp Time ≥ 4 hours, OR
  • Estimated Cross Clamp Time ≥ 2 hours, AND Any ONE or more of the following:
    • Age ≥ 50 years
    • LVEF 40-50% at time of provisional acceptance
    • Down-time ≥ 20 mins
    • Hypertrophy/Septal thickness >12- ≤16mm
    • Angiographic luminal irregularities with no significant CAD, OR
  • Donation after Circulatory Death (DCD) donors.

Donor Exclusion Criteria:

  • Unstable hemodynamics requiring high-dose inotropic support.
  • Significantly abnormal coronary angiogram defined as CAD > 50% stenosis of one or more vessels.
  • Moderate to severe cardiac valve pathology.
  • Investigator's clinical decision to exclude from trial.
  • Previous Sternotomy.

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Share:
Study Stats
Protocol No.
23-5202
Category
Heart/Cardiovascular Diseases
Immune System/Transplant Related Disorders
Contact
JASMYN AKANINWOR
Location
  • UCLA Westwood
For Providers
NCT No.
NCT05881278
For detailed technical eligibility, visit ClinicalTrials.gov.